INTRODUCTION
The induction of B-lymphocyte growth and differentiation by surface receptors such as membrane IgM (mIgM) and the protein kinase C (PKC) agonist, phorbol 12-myristate 13-acetate (PMA), is dependent on reversible phosphorylation of proteins [1] . Although the roles of protein kinases have been extensively explored in B-cells, not much is known about the role of phosphatases in signalling. Protein phosphatases are clearly important, since lymphocytes contain all four major serine/ threonine protein phosphatase (PP) activities: PP1, PP2A, PP2B and PP2C [2] [3] [4] . It has become possible to study the role of PPl and PP2A in mammalian cells more directly due to the availability of okadaic acid (OA), a potent and specific inhibitor of these phosphatases in vitro as well as in intact cells [2] [3] [4] . Moreover, OA is a tumour promoter in mouse skin, which suggests that OA affects the phosphorylation of substrates involved in cellular growth [2, 5] .
As one may expect from a serine/threonine phosphatase inhibitor, the result of OA treatment is complex and can affect the phosphorylation of a large number of intracellular proteins [2] . We were particularly interested in the effect of OA on p42 microtubule-associated protein-2 kinase (MAP-2K), also known as mitogen-activated protein kinase (MAP kinase), which is controlled by a process of reversible phosphorylation [1, 6, 7] . MAP kinase is a serine kinase which is activated during mIgM ligation or PMA treatment of B-lymphocytes [1] and is identical to p42MAPK, which is induced by a variety of growth factor receptors in fibroblasts, adipocytes and neuronal cells [8] [9] [10] [11] . p42MAPK belongs to a kinase family some of the members of which have been cloned and are included in the extracellular incorporation into normal human tonsil B-cells. Moreover, in combination with membrane immunoglobulin M ligation, okadaic acid decreased rather than increased [3H]thymidine incorporation. The kinetics of MAP kinase activation by okadaic acid differed from phorbol 12-myristate 13-acetate and antimembrane immunoglobulin M stimulation. Okadaic acid induced tyrosine phosphorylation of 42 kDa and 44 kDa proteins which co-electrophoresed and co-chromatographed with ERK-2 and ERK-1 respectively. Ramos cells also contained a constitutively active 46 kDa MAP kinase which appeared as a separate peak in chromatography and could be immunoprecipitated by an antiserum against a rat ERK-1 fusion protein.
signal-regulated kinase (ERK) family [12] . According to the latter nomenclature, ERK-I represents p44 MAP-2K or p44MAPK and ERK-2 is p42 MAP-2K or p42MAPK [12, 13] . p42MAPK phosphorylates several substrates in vitro, including microtubuleassociated protein-2 (MAP-2) and a peptide, APRTPGGRR, which constitutes a consensus site for MAP-kinase phosphorylation in bovine myelin basic protein (MBP) [13] . The kinase itself is a threonine and tyrosine phosphoprotein and can be inactivated by CD45, a tyrosine phosphatase, and PP2A, a serine/threonine phosphatase [14] . There is much debate currently as to whether the addition of the threonine and tyrosine phosphate groups to p42MAPK reflects the effect of afferent kinases or autophosphorylation; however, in T-lymphocytes we and others have shown that the tyrosine protein kinase (TPK) p561ck may be involved [15] [16] [17] .
It has been shown that OA can induce p42 MAP kinase activity in fibroblasts and PC12 cells [6, 7, 18] . We were interested to see whether PP1/PP2A exert the same effect in B-lymphocytes and if this biomedical response, as for PMA, is associated with cellular growth. In the Ramos B-lymphoblastoid cell line, we were able to demonstrate an OA-activated MAP kinase activity which co-chromatographed with ERK-2 (p42MAPK) and ERK-1 (p44MAPK). PMA 
Mono-Q chromatography
Large-scale purification of MAP kinase was carried out by sonication lysis of 200 x 106 stimulated or unstimulated cells in 3 ml of buffer B, containing 50 mM /8-glycerophosphate, 1.5 mM EGTA, 100 ,uM Na3VO4, 1 mM dithiothreitol, 1 mM benzamidine, leupeptin (10,ug/ml) and aprotinin (100 ,tg/ml) (pH 7.3) [9] . Subsequently, the lysate was centrifuged at 100000 g at 4°C for 20 min. Equal amounts of supernatant protein (12 mg) were loaded onto a 1.5 cm x 2 cm Mono-Q column, followed by washing with 40 ml of buffer B. The column was eluted in 0.5 ml fractions by 45 ml of a linear 0-400 mM NaCl gradient. MAP kinase activity was determined in even-numbered fractions.
Phosphorylation protocols [1, 16, [23] [24] [25] . We have previously shown that this assay selects for MAP kinase [1, 16] . Confirmation of the specificity of the kinase was also sought by in vitro phosphorylation of a specific MAP kinase peptide substrate, APRTPGGRR (results not shown) [13] . The phosphorylated peptide was absorbed onto 2 cm x 2 cm phosphocellulose squares which were washed in 10 mM H3PO4 and counted for radioactivity [13] .
Immunoblotting
The soluble fraction from 3 x 106 resting or stimulated (antiIgM, PMA, OA) Ramos cells were boiled with 3 x SDS sample buffer and resolved by SDS/PAGE (10% gels). After electrophoretic transfer to Immobilin-P membranes, these were blocked for 2 h at 20°C in 6 % bovine serum albumin (fraction V), 0. Table 2 ). The optimal stimulatory dose was 0.5-1 ,M, which is in agreement with previous findings and the estimated intracellular concentration of these phosphatases [2, 4, 6] . Similar results were obtained in normal human tonsillar B-lymphocytes (not shown). MAP [2, 5] . Both induced MAP kinase activity in B lymphocytes (Figure 1 (Figure la) . Furthermore, costimulation of Ramos cells with anti-IgM and OA yielded dual activation, with a peak at 5 min and then beginning to rise again after 30 min ( Figure Ib) . These activities coincide with antiTime (min) Figure 1 OA, PMA and a-lgM activate MAP kinase with unique kinetcs (a) Ramos cells were stimulated with 1 ,ug/ml biotinylated anti-lgM (secondarily crosslinked with 50 ,ug/ml avidin), 50 nM PMA and 1 ,uM OA for the time periods indicated. MAP kinase activity was purified by DEAE batch absorption and in vitro activity measured by the ability to phosphorylate MAP-2 protein as described [23] [24] [25] . (b) The combination of 1 1sM OA and 1 ,tg/ml anti-lgM plus 50 jug/ml avidin was added at time zero. PMA accompanied more rapid MAP kinase activation by the same agent (Figure 2a ). When the APT immunoblot shown in Figure 2 (a) was reprobed with antiserum 691, a 42/44 kDa doublet representing ERK-2 and ERK-1, respectively, was seen to co-electrophorese with p42 and p44 (Figure 2b ) [20] . Although post-translational modification of MAP kinases results in electrophoretic retardation, this SDS/PAGE analysis did not show a mobility shift (Figure 2b ), but such an effect could be seen in other experiments (data not shown).
OA and PMA both activate the same peak of MAP kinase activity during Mono-U chromatography
Lysates obtained from PMA-and OA-treated cells after fractionation on Mono-Q columns yielded two peaks of activity which phosphorylate MAP-2 protein. Peak I eluted at 100-200 mM NaCl, while peak II eluted at 300-380 mM NaCl (Figure 3 ). The same profile was obtained when the MBP peptide was used as substrate (data not shown). Unstimulated cells contained a single peak of activity, peak I (Figure 3 ). The relative abundance of peak I activity was only slightly less than in stimulated cells, which implies that this is a constitutively active kinase (Figure 3 ).
Peak II, in contrast, is clearly an inducible activity. In order to determine how these peaks relate to the proteins detected in Figure 2 (a), we immunoblotted Mono-Q fractions ( Figure 3 ) from control, OA-, and PMA-treated samples with antiserum 691 [20] . Immunoblotting revealed a 42/44 kDa doublet which was present in peak II of OA- (Figure 4b ) as well as PMA- (Figure 4c ) treated populations, but was absent from peak I or the trough between these peaks (Figures 4a, 4b and 4c ). In contrast, untreated Ramos cells yielded only small amounts of the 42/44 kDa doublet at the start of peak II (Figure 4a Table 4 Binding of peak I to antl-ERK fusion protein antiserum
The IgG fraction of the anti-ERK fusion antiserum was immobilized on a column (Hydrazide Avidchrom) and a 1.0 ml aliquot of peak material (control cell fractions 26 and 27) was allowed to bind. The starting material (peak 1) and non-bound fractions were assayed for MAP kinase activity using MAP-2 protein as the substrate. The column was washed with 10 ml of buffer B and eluted with 50 mM glycine/HCI (pH 2.0). Fractions of 0.5 ml were collected and neutralized with 15 ,ul of 1 mM Tris-base. MAP kinase activity was recovered in fraction 8 (0.5 ml). Results are expressed as a percentage of total activity in starting material (peak 1). 1. In order to prove that the 46 kDa protein is a MAP kinase, we immobilized the IgG fraction of our antiserum to a support resin and passed an aliquot of peak I (from control cells) through the column. More than 80 % of initial MAP kinase activity bound to the column (Table 4 ). About half of the initial activity could be recovered by elution with an acidic buffer ( Table 4 ). This suggests that a major portion of peak I kinase activity is contained in an unidentified but constitutively active 46 kDa MAP kinase. 
DISCUSSION
In this paper, we provide evidence for the diverse effects of OA on B-lymphocyte mitogenesis. Although OA activated an early biochemical event associated with cellular growth, it failed to promote [3H]TdR uptake at the intact cell level. This implies that PP1/PP2A may exert both stimulatory and inhibitory effects at different stages of the cell cycle.
The progression of B-lymphocytes through the cell cycle is dependent on reversible phosphorylation of signalling intermediates. Although some knowledge exists about the role of protein kinases in these events, not much is understood about the role of phosphatases. With the introduction of OA, it was possible to study the effect of PPl/PP2A at the intact cell level and relate this to a signalling response, namely the activation of MAP kinase. We show that OA induced MAP kinase activity in a dose-and time-dependent fashion in normal human Blymphocytes as well as the B-lymphoblastoid cell line, Ramos (Tables 1 and 2 , Figure 1) . MAP kinase has the potential to regulate transcriptional activity through phosphorylation of cjun and c-myc, and also activates ribosomal S6 kinase II (p90) [26] [27] [28] . It is probably relevant, therefore, that OA has been found to induce AP-1 activity in human lymphocytes by tran- scriptional activation ofjun andfos [29] . In spite of activating a signalling pathway associated with cellular growth, OA failed to stimulate growth of normal human B-lymphocytes (Table 3 ).
This contrasts with the effect of another tumour promoter and MAP kinase inducer, PMA [1] . PMA is a PKC agonist and a potent B-cell mitogen (Table 3) . The difference in the biological response to PMA and to OA probably derives from the ability of the latter agent to exert more diverse effects than PMA. The range of OA substrates may include phosphoproteins that act downstream of MAP kinase but in an opposing fashion. In this paper we have not attempted to define the substrates or points in the cycle at which OA inhibits cycle events, but it is interesting that Metcalfe and Milner have previously shown that delayed addition of OA to concavalin A (Con A)-stimulated T-lymphocytes prevented these cells from entering S phase [30] . As defined by Mono-Q chromatography, OA induced the same peak of MAP kinase activity as did PMA (Figure 3 ). This peak co-chromatographed with ERK-1 and ERK-2, as defined by immunoblotting with antiserum 691 (Figure 4 ). In crude cell lysates, OA and PMA induced tyrosine phosphorylation of 42 kDa and 44 kDa proteins which co-electrophoresed with ERK-2 and ERK-1 respectively (Figure 2 ). The kinetics of tyrosine phosphorylation of these proteins differed for OA and PMA in accordance with their kinetics of MAP kinase activation (Figures 1 and 2 ). This indicates possible differences in the way in which these tumour promoters trigger the MAP kinase cascade, an idea which was further supported by dual MAP kinase responses when Ramos cells were simultaneously stimulated with anti-IgM and OA (Figure 2b ). MAP kinase activation by mIgM is partially dependent on PKC [1] . Although the mechanisms of activation by PMA and OA remain to be elucidated, it would appear that tyrosine phosphorylation of ERK-1 and ERK-2 is common to both pathways (Figure 2a) . Afferent signalling components which could theoretically be affected by serine/ threonine phosphorylation include TPKs [17] , a MAP kinase activator [31] , and a MAP kinase kinase [32] . Experimental evide'nce for each of these afferent events exists, which implies that several afferent pathways may converge on MAP kinase [31] [32] [33] .
The presence of a constitutively active MAP kinase was an interesting finding during fractionation of crude cell lysates on Mono-Q columns (Figure 3 ). We found that peak I MAP kinase co-eluted with a 46 kDa protein, which binds to an antibody to an ERK-1 fusion protein and so is ERK-1 related (Figure 4e ). Using an immunoaffinity approach (Table 4) , we demonstrated that this protein is a MAP kinase. Peak I also phosphorylated the MBP peptide, APRTPGGRR (results not shown). The inability of Ab 691 to bind to peak I material means that this protein differs from conventional ERK-1. This kinase requires further study and may have a different role from that of p42 MAP kinase.
